Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Carolwood Marketing EFAin EU as Diabetes Treatment
May 28, 2001
1 Min Read
Carolwood Marketing EFAin EU as Diabetes Treatment
GREENVILLE, Pa.--CarolwoodCorp. is marketing its essential fatty acid (EFA) supplement, Entrox, as atreatment for Type II diabetes and for controlling risk factors for the disease. In addition, the company is sponsoring a clinical study on the effectiveness of Entrox in improving long-term blood sugar levelsin diabetics; the placebo-controlled, double-blind study will be conducted at the Medical University of Bonn, Germany, and should finish by October 2001. Details on Entrox are available atwww.msm.com.
You May Also Like
